Related Experiment Video
Updated: Aug 7, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
International consensus statement on allergy and rhinology: Allergic rhinitis - 2023
Sarah K Wise1, Cecelia Damask2, Lauren T Roland3
1Otolaryngology-HNS, Emory University, Atlanta, Georgia, USA.
The International Consensus Statement on Allergy and Rhinology 2023 provides an updated, evidence-based review of 144 topics in allergic rhinitis (AR). This comprehensive document guides current patient evaluation and treatment strategies.
Area of Science:
- Otolaryngology
- Allergy and Immunology
Background:
- The 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR-Allergic Rhinitis 2018) has been significantly updated.
- Substantial expansion in literature necessitated a comprehensive review of allergic rhinitis (AR).
Purpose of the Study:
- To present an updated, evidence-based evaluation of 144 topics related to allergic rhinitis (AR).
- To incorporate new findings and revise existing knowledge since the 2018 consensus statement.
Main Methods:
- Utilized the established evidence-based review with recommendation (EBRR) methodology.
- Conducted stepwise iterative peer review and consensus for each of the 144 topics.
- Collated aggregate grades of evidence and developed recommendation summaries.
Main Results:
- The 2023 update covers 10 major content areas and 144 individual topics on AR.
- Aggregate grades of evidence are presented for a substantial proportion of topics.
- Recommendation summaries consider evidence, benefit, harm, and cost for interventions.
Conclusions:
- ICAR-Allergic Rhinitis 2023 offers a comprehensive assessment of current AR knowledge.
- The updated evidence base informs contemporary recommendations for AR patient evaluation and treatment.
Related Concept Videos
Allergic Reactions
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

